UBS/CALL/ELI LILLY & CO/900.001/0.01/20.12.24 | Real-time Bid/Ask 08:46:34 2024-05-23 am EDT | ||
| 0.47 CHF / 0.49 CHF | +2.13% |
|
| Current month | +27.03% | ||
| 1 month | +46.88% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-05-21 | 0.47 | +27.03% |
| 24-05-16 | 0.37 | -2.63% |
| 24-05-15 | 0.38 | +26.67% |
Delayed Quote Swiss Exchange
Last update May 21, 2024 at 11:20 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | UBS |
| LLYGBU | |
| ISIN | CH1312533784 |
| Date issued | 2024-01-08 |
| Strike | 900 $ |
| Maturity | 2024-12-20 (211 Days) |
| Parity | 100 : 1 |
| Emission price | 0.11 CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 0.57 CHF |
|---|---|
| Lowest since issue | 0.12 CHF |
| Spread | 0.02 CHF |
| Spread % | 4.08% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
802.9
USD
Average target price
850.4
USD
Spread / Average Target
+5.92%
- Stock Market
- Warrants
- LLYGBU Warrant
